Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Repayments: 2014-2020

Historic Long-Term Debt Repayments for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Dec 2020 value amounting to $9.0 million.

  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments rose 796.00% to $9.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $11.3 million, marking a year-over-year increase of 105.33%. This contributed to the annual value of $10.3 million for FY2020, which is 341.19% up from last year.
  • According to the latest figures from Q4 2020, Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments is $9.0 million, which was up 2,590.69% from $333,000 recorded in Q2 2020.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments ranged from a high of $9.0 million in Q4 2020 and a low of $333,000 during Q4 2016.
  • Its 2-year average for Long-Term Debt Repayments is $2.1 million, with a median of $1.0 million in 2020.
  • Data for Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments shows a peak YoY spiked of 1,565.00% (in 2016) over the last 5 years.
  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments (Quarterly) stood at $333,000 in 2016, then surged by 851.05% to $3.2 million in 2017, then reached $1.0 million in 2019, then spiked by 796.00% to $9.0 million in 2020.
  • Its Long-Term Debt Repayments was $9.0 million in Q4 2020, compared to $333,000 in Q2 2020 and $1.0 million in Q1 2020.